Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases.
作者信息
Mehta Nehal N
机构信息
Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, USA.
出版信息
Cardiovasc Res. 2018 Sep 1;114(11):e81-e83. doi: 10.1093/cvr/cvy160.
Abstract
摘要
相似文献
1
Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases.Janus激酶抑制剂在免疫介导疾病中的潜在心血管影响。
Cardiovasc Res. 2018 Sep 1;114(11):e81-e83. doi: 10.1093/cvr/cvy160.
2
Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.JAK 抑制剂的开发用于治疗免疫介导的疾病：激酶靶向抑制剂和假激酶靶向抑制剂。
Arch Pharm Res. 2020 Nov;43(11):1173-1186. doi: 10.1007/s12272-020-01282-7. Epub 2020 Nov 8.
3
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK 抑制作为治疗免疫和炎症性疾病的策略。
Nat Rev Drug Discov. 2017 Dec;16(12):843-862. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.
4
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.Janus激酶抑制剂：其在皮肤科新兴应用的综述
Skin Therapy Lett. 2018 May;23(3):5-9.
5
Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.银屑病的新型治疗方法包括白细胞介素 23 抑制剂、磷酸二酯酶 4 抑制剂和 Janus 激酶抑制剂。
Dermatol Ther. 2017 Nov;30(6). doi: 10.1111/dth.12555. Epub 2017 Oct 10.
6
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Janus 激酶抑制剂在炎症性肠病中的未来。
J Crohns Colitis. 2017 Jul 1;11(7):885-893. doi: 10.1093/ecco-jcc/jjx003.
7
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.JAK 抑制剂的问世：推进免疫和血液疾病治疗的进展。
BioDrugs. 2013 Oct;27(5):431-8. doi: 10.1007/s40259-013-0040-7.
8
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.用于治疗炎症性和肿瘤性疾病的 Janus 激酶（JAK）抑制剂
Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26.
9
[All about JAK inhibitors].[关于JAK抑制剂的一切]
Rev Med Interne. 2024 Sep;45(9S1):S9-S12. doi: 10.1016/S0248-8663(24)00775-6.
10
Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.发现强效抗炎 4-(4,5,6,7-四氢呋喃[3,2-c]吡啶-2-基)嘧啶-2-胺类作为 Janus 激酶抑制剂的用途。
Bioorg Med Chem. 2019 Jun 15;27(12):2592-2597. doi: 10.1016/j.bmc.2019.03.048. Epub 2019 Mar 25.
引用本文的文献
1
Cardiovascular toxicities associated with immune checkpoint inhibitors.免疫检查点抑制剂相关的心血管毒性。
Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026.
本文引用的文献
1
Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.两种银屑病治疗方法对血管炎症和新型炎症性心血管生物标志物的影响：一项随机安慰剂对照试验。
Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394. doi: 10.1161/CIRCIMAGING.117.007394.
2
From clinical observations to molecular mechanisms and back to patients: the successful circuit of the CANTOS study.从临床观察到分子机制，再回归患者：CANTOS研究的成功循环。
Cardiovasc Res. 2018 Jan 1;114(1):e3-e5. doi: 10.1093/cvr/cvx219.
3
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK 抑制作为治疗免疫和炎症性疾病的策略。
Nat Rev Drug Discov. 2017 Dec;16(12):843-862. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.
4
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.银屑病患者血液中炎症和心血管蛋白的减少：治疗 4 周后托法替尼和依那西普的差异反应。
J Invest Dermatol. 2018 Feb;138(2):273-281. doi: 10.1016/j.jid.2017.08.040. Epub 2017 Sep 18.
5
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
6
Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.托法替布对中重度银屑病患者血脂水平及血脂相关参数的影响。
J Clin Lipidol. 2017 Sep-Oct;11(5):1243-1256. doi: 10.1016/j.jacl.2017.06.012. Epub 2017 Jun 24.
7
The emerging safety profile of JAK inhibitors in rheumatic disease.新型 JAK 抑制剂在风湿性疾病中的安全性概况。
Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2.
8
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.巴瑞替尼对活动期类风湿关节炎患者的血脂、载脂蛋白和脂蛋白颗粒谱的影响：一项 IIb 期研究。
Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.
9
Psoriasis.银屑病。
Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82.
10
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.基于斑块型银屑病患者的 III 期和长期扩展数据，评估托法替尼对心血管危险因素和心血管结局的影响。
J Am Acad Dermatol. 2016 Nov;75(5):897-905. doi: 10.1016/j.jaad.2016.06.012. Epub 2016 Aug 4.
Zotero 插件